{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:37:13Z","timestamp":1792456633793,"version":"4.5.0"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Regen"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Diabetes mellitus is a common and serious metabolic disease globally, characterized by increased blood glucose levels. The major pathogenesis is the functional impairment of insulin-producing beta cells in the pancreas and the lack of insulin secretion. Although both type 1 and type 2 diabetes develop through distinct pathological mechanisms, they lead to the destruction and\/or dysfunction of beta cells, resulting in inadequate beta cell mass to maintain normal blood glucose levels. For this reason, therapeutic agents capable of inducing beta cell proliferation can be considered a possible approach to restore beta cell abundance and treat type 1 and type 2 diabetes. Although several methods have been found to promote the replication of beta cells in animal models or cell lines, it is still challenging to promote the effective proliferation of beta cells in humans. This review highlights the different agents and mechanisms that facilitate pancreatic beta cell regeneration. Numerous small molecules have been discovered to influence beta cell proliferation, primarily by targeting cellular pathways such as DYRK1A, adenosine kinase, SIK, and glucokinase. Additionally, receptors for TGF-\u03b2, EGF, insulin, glucagon, GLP-1, SGLT2 inhibitors, and prolactin play critical roles in this process. Stem cell-based clinical trials are also underway to assess the safety and efficacy of stem cell therapies for patients with type 1 and type 2 diabetes. We have emphasized alternative therapeutic pathways and related strategies that may be employed to promote the regeneration of pancreatic beta cells. The knowledge raised within this review may help to understand the potential drug-inducible targets for beta cell regeneration and pave the way for further investigations.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1186\/s13619-025-00255-9","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T01:01:49Z","timestamp":1757120509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Drug-induced regeneration of pancreatic beta cells: An approach to cellular therapeutic targets"],"prefix":"10.1186","volume":"14","author":[{"given":"Parinaz","family":"Parsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saber","family":"Saharkhiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh Ramezani","family":"Farani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salar","family":"Bakhtiyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-8606","authenticated-orcid":false,"given":"Iraj","family":"Alipourfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"255_CR1","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1210\/EN.2018-00083","volume":"159","author":"Y Abdolazimi","year":"2018","unstructured":"Abdolazimi Y, Zhao Z, Lee S, Xu H, Allegretti P, Horton TM, et al (2018) CC-401 promotes \u03b2-cell replication via pleiotropic consequences of DYRK1A\/B inhibition. Endocrinology. 159:3143\u201357. https:\/\/doi.org\/10.1210\/EN.2018-00083.","journal-title":"Endocrinology"},{"key":"255_CR2","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.2337\/DB13-0604","volume":"62","author":"MA Abdul-Ghani","year":"2013","unstructured":"Abdul-Ghani MA, DeFronzo RA, Norton L (2013) Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30\u201350% of filtered glucose load in humans. Diabetes. 62:3324\u20138. https:\/\/doi.org\/10.2337\/DB13-0604.","journal-title":"Diabetes"},{"key":"255_CR3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1172\/JCI.INSIGHT.132594","volume":"5","author":"C Ackeifi","year":"2020","unstructured":"Ackeifi C, Swartz E, Kumar K, Liu H, Chalada S, Karakose E, et al (2020) Pharmacologic and genetic approaches define human pancreatic \u03b2 cell mitogenic targets of DYRK1A inhibitors. JCI Insight. 5:366\u201374. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.132594.","journal-title":"JCI Insight"},{"key":"255_CR4","doi-asserted-by":"publisher","unstructured":"Ackeifi C, Wang P, Karakose E, Manning Fox JE, Gonz\u00e1lez BJ, Liu H, et al (2020b) GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human \u03b2 cell regeneration. Sci Transl Med.;12. https:\/\/doi.org\/10.1126\/scitranslmed.aaw9996.","DOI":"10.1126\/scitranslmed.aaw9996"},{"key":"255_CR5","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.2337\/DC12-2006\/-\/DC1","volume":"36","author":"B Ahr\u00e9n","year":"2013","unstructured":"Ahr\u00e9n B, Dimas AL, Miossec P, Saubadu S, Aronson R (2013) Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 36:2543\u201350. https:\/\/doi.org\/10.2337\/DC12-2006\/-\/DC1.","journal-title":"Diabetes Care"},{"key":"255_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/J.ECLINM.2024.102782","volume":"75","author":"N Alfaris","year":"2024","unstructured":"Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC (2024) GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 75: 102782. https:\/\/doi.org\/10.1016\/J.ECLINM.2024.102782.","journal-title":"EClinicalMedicine"},{"key":"255_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/1566524020666200427102209","volume":"21","author":"I Alipourfard","year":"2020","unstructured":"Alipourfard I, Bakhtiyari S, Gheysarzadeh A, Di RL, De LA, Mikeladze D, et al (2020) The Key Role of Akt Protein Kinase in Metabolic-Inflammatory Pathways Cross-Talk: TNF-\u03b1 Down-Regulation and Improving of Insulin Resistance in HepG2 Cell Line. Curr Mol Med. 21:257\u201364. https:\/\/doi.org\/10.2174\/1566524020666200427102209.","journal-title":"Curr Mol Med"},{"key":"255_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/J.BMC.2019.115193","volume":"28","author":"PA Allegretti","year":"2020","unstructured":"Allegretti PA, Horton TM, Abdolazimi Y, Moeller HP, Yeh B, Caffet M, et al (2020) Generation of highly potent DYRK1A-dependent inducers of human \u03b2-Cell replication via Multi-Dimensional compound optimization. Bioorg Med Chem.28: 115193. https:\/\/doi.org\/10.1016\/J.BMC.2019.115193.","journal-title":"Bioorg Med Chem"},{"key":"255_CR9","doi-asserted-by":"publisher","unstructured":"Aloke C, Egwu CO, Aja PM, Obasi NA, Chukwu J, Akumadu BO, et al (2022) Current Advances in the Management of Diabetes Mellitus. Biomedicines 10. https:\/\/doi.org\/10.3390\/biomedicines10102436.","DOI":"10.3390\/biomedicines10102436"},{"key":"255_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315609312","volume":"7","author":"SL Anderson","year":"2016","unstructured":"Anderson SL, Trujillo JM (2016) Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Ther Adv Chronic Dis. 7: 4. https:\/\/doi.org\/10.1177\/2040622315609312.","journal-title":"Ther Adv Chronic Dis"},{"key":"255_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.cmet.2012.04.018","volume":"15","author":"O Andersson","year":"2012","unstructured":"Andersson O, Adams BA, Yoo D, Ellis GC, Gut P, Anderson RM, et al (2012) Adenosine signaling promotes regeneration of pancreatic \u03b2 cells in vivo. Cell Metab. 15:885\u201394. https:\/\/doi.org\/10.1016\/j.cmet.2012.04.018.","journal-title":"Cell Metab"},{"key":"255_CR12","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1073\/PNAS.1201149109\/-\/DCSUPPLEMENTAL\/PNAS.201201149SI.PDF","volume":"109","author":"JP Annes","year":"2012","unstructured":"Annes JP, Ryu JH, Lam K, Carolan PJ, Utz K, Hollister-Lock J, et al (2012a) Adenosine kinase inhibition selectively promotes rodent and porcine islet \u03b2-cell replication. Proc Natl Acad Sci U S A. 109:3915\u201320. https:\/\/doi.org\/10.1073\/PNAS.1201149109\/-\/DCSUPPLEMENTAL\/PNAS.201201149SI.PDF.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"255_CR13","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1073\/PNAS.1201149109\/SUPPL_FILE\/PNAS.201201149SI.PDF","volume":"109","author":"JP Annes","year":"2012","unstructured":"Annes JP, Ryu JH, Lam K, Carolan PJ, Utz K, Hollister-Lock J, et al (2012b) Adenosine kinase inhibition selectively promotes rodent and porcine islet \u03b2-cell replication. Proc Natl Acad Sci U S A. 109:3915\u201320. https:\/\/doi.org\/10.1073\/PNAS.1201149109\/SUPPL_FILE\/PNAS.201201149SI.PDF.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 4","key":"255_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/J.1463-1326.2008.00949.X","volume":"10","author":"L Baeyens","year":"2008","unstructured":"Baeyens L, Bouwens L (2008) Can beta-cells be derived from exocrine pancreas? Diabetes Obes Metab. 10(Suppl 4):170\u20138. https:\/\/doi.org\/10.1111\/J.1463-1326.2008.00949.X.","journal-title":"Diabetes Obes Metab"},{"key":"255_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/S00125-004-1606-1","volume":"48","author":"L Baeyens","year":"2005","unstructured":"Baeyens L, De Breuck S, Lardon J, Mfopou JK, Rooman I, Bouwens L (2005) In vitro generation of insulin-producing beta cells from adult exocrine pancreatic cells. Diabetologia. 48:49\u201357. https:\/\/doi.org\/10.1007\/S00125-004-1606-1.","journal-title":"Diabetologia"},{"key":"255_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/DOM.12716","volume":"18","author":"L Baeyens","year":"2016","unstructured":"Baeyens L, Hindi S, Sorenson RL, German MS (2016) \u03b2-Cell adaptation in pregnancy. Diabetes, Obes Metab. 18:63\u201370. https:\/\/doi.org\/10.1111\/DOM.12716.","journal-title":"Diabetes, Obes Metab"},{"key":"255_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/BJ20070797","volume":"408","author":"J Bain","year":"2007","unstructured":"Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, Mclauchlan H, et al (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J. 408:297. https:\/\/doi.org\/10.1042\/BJ20070797.","journal-title":"Biochem J"},{"key":"255_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S11892-019-1176-8\/METRICS","volume":"19","author":"G Basile","year":"2019","unstructured":"Basile G, Kulkarni RN, Morgan NG (2019) How, When, and Where Do Human \u03b2-Cells Regenerate? Curr Diab Rep. 19:1\u201312. https:\/\/doi.org\/10.1007\/S11892-019-1176-8\/METRICS.","journal-title":"Curr Diab Rep"},{"key":"255_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/J.MOLMET.2022.101477","volume":"60","author":"G Basile","year":"2022","unstructured":"Basile G, Qadir MMF, Mauvais-Jarvis F, Vetere A, Shoba V, Modell AE, et al (2022) Emerging diabetes therapies: Bringing back the \u03b2-cells. Mol Metab. 60: 101477. https:\/\/doi.org\/10.1016\/J.MOLMET.2022.101477.","journal-title":"Mol Metab"},{"key":"255_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2337\/DB21-0581","volume":"71","author":"S Baumel-Alterzon","year":"2022","unstructured":"Baumel-Alterzon S, Katz LS, Brill G, Jean-Pierre C, Li Y, Tse I, et al (2022) Nrf2 regulates \u03b2-cell mass by suppressing \u03b2-cell death and promoting \u03b2-cell proliferation. Diabetes. 71:989. https:\/\/doi.org\/10.2337\/DB21-0581.","journal-title":"Diabetes"},{"key":"255_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/J.CELL.2016.11.002","volume":"168","author":"N Ben-Othman","year":"2017","unstructured":"Ben-Othman N, Vieira A, Courtney M, Record F, Gjernes E, Avolio F, et al (2017) Long-term GABA administration induces alpha cell-mediated beta-like cell neogenesis. Cell. 168:73-85.e11. https:\/\/doi.org\/10.1016\/J.CELL.2016.11.002.","journal-title":"Cell"},{"key":"255_CR22","doi-asserted-by":"publisher","first-page":"31950","DOI":"10.1074\/JBC.M303127200","volume":"278","author":"I Ber","year":"2003","unstructured":"Ber I, Shternhall K, Perl S, Ohanuna Z, Goldberg I, Barshack I, et al (2003) Functional, persistent, and extended liver to pancreas transdifferentiation. J Biol Chem. 278:31950\u20137. https:\/\/doi.org\/10.1074\/JBC.M303127200.","journal-title":"J Biol Chem"},{"key":"255_CR23","doi-asserted-by":"publisher","unstructured":"Berneman-Zeitouni D, Molakandov K, Elgart M, Mor E, Fornoni A, Dom\u00ednguez MR, et al (2014) The temporal and hierarchical control of transcription factors-induced liver to pancreas transdifferentiation. PLoS One 9. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0087812.","DOI":"10.1371\/JOURNAL.PONE.0087812"},{"key":"255_CR24","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.4161\/cc.20036","volume":"11","author":"M Blandino-Rosano","year":"2012","unstructured":"Blandino-Rosano M, Chen AY, Scheys JO, Alejandro EU, Gould AP, Taranukha T, et al (2012) MTORC1 signaling and regulation of pancreatic \u03b2-cell mass. Cell Cycle. 11:1892\u2013902. https:\/\/doi.org\/10.4161\/cc.20036.","journal-title":"Cell Cycle"},{"key":"255_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/S12020-012-9755-3","volume":"43","author":"D Boj-Carceller","year":"2013","unstructured":"Boj-Carceller D (2013) Proton pump inhibitors: impact on glucose metabolism. Endocrine. 43:22\u201332. https:\/\/doi.org\/10.1007\/S12020-012-9755-3.","journal-title":"Endocrine"},{"key":"255_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1210\/EDRV.19.3.0334","volume":"19","author":"C Bole-Feysot","year":"1998","unstructured":"Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998) Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice. Endocr Rev. 19:225\u201368. https:\/\/doi.org\/10.1210\/EDRV.19.3.0334.","journal-title":"Endocr Rev"},{"key":"255_CR27","doi-asserted-by":"publisher","unstructured":"Bonora E, Frias JP, Tinahones FJ, Van J, Malik RE, Yu Z, et al (2021) Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11. Diabetes Obes Metab 23:2242\u201350. https:\/\/doi.org\/10.1111\/DOM.14465.","DOI":"10.1111\/DOM.14465"},{"key":"255_CR28","doi-asserted-by":"publisher","unstructured":"Bourgeois S, Coenen S, Degroote L, Willems L, Van Mulders A, Pierreux J, Heremans Y, De Leu N, Staels W (2024) Harnessing beta cell regeneration biology for diabetes therapy. https:\/\/doi.org\/10.1016\/j.tem.2024.03.006.","DOI":"10.1016\/j.tem.2024.03.006"},{"key":"255_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/J.SCR.2013.10.003","volume":"12","author":"JE Bruin","year":"2014","unstructured":"Bruin JE, Erener S, Vela J, Hu X, Johnson JD, Kurata HT, et al (2014) Characterization of polyhormonal insulin-producing cells derived in vitro from human embryonic stem cells. Stem Cell Res. 12:194\u2013208. https:\/\/doi.org\/10.1016\/J.SCR.2013.10.003.","journal-title":"Stem Cell Res"},{"key":"255_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/J.CLINTHERA.2016.01.014","volume":"38","author":"S Brunton","year":"2016","unstructured":"Brunton S, Davidson JA (2016) Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes. Clin Ther. 38:582\u201394. https:\/\/doi.org\/10.1016\/J.CLINTHERA.2016.01.014.","journal-title":"Clin Ther"},{"key":"255_CR31","doi-asserted-by":"publisher","unstructured":"Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al (2020) 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63:221\u20138. https:\/\/doi.org\/10.1007\/S00125-019-05039-W,.","DOI":"10.1007\/S00125-019-05039-W"},{"key":"255_CR32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/J.1463-1326.2008.00992.X","volume":"11","author":"MA Bush","year":"2009","unstructured":"Bush MA, Matthews JE, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, et al (2009) Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 11:498\u2013505. https:\/\/doi.org\/10.1111\/J.1463-1326.2008.00992.X.","journal-title":"Diabetes Obes Metab"},{"key":"255_CR33","doi-asserted-by":"publisher","unstructured":"Butler AE, Cao-Minh L, R. Galasso, Rizza RA, Corradin A, Cobelli C, et al (2010) Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia 53:2167\u201376. https:\/\/doi.org\/10.1007\/S00125-010-1809-6\/FIGURES\/6.","DOI":"10.1007\/S00125-010-1809-6\/FIGURES\/6"},{"key":"255_CR34","doi-asserted-by":"publisher","unstructured":"Cerf ME (2013) Beta Cell Dysfunction and Insulin Resistance. Front Endocrinol (Lausanne) 4. https:\/\/doi.org\/10.3389\/FENDO.2013.00037.","DOI":"10.3389\/FENDO.2013.00037"},{"key":"255_CR35","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/HEP.31859","volume":"74","author":"BKY Chan","year":"2021","unstructured":"Chan BKY, Elmasry M, Forootan SS, Russomanno G, Bunday TM, Zhang F, et al (2021) Pharmacological activation of Nrf2 enhances functional liver regeneration. Hepatology. 74:973\u201386. https:\/\/doi.org\/10.1002\/HEP.31859.","journal-title":"Hepatology"},{"key":"255_CR36","doi-asserted-by":"publisher","unstructured":"Charbord J, Ren L, Sharma RB, Johansson A, \u00c5gren R, Chu L, et al (2021) In vivo screen identifies a SIK inhibitor that induces \u03b2 cell proliferation through a transient UPR. Nat Metab.3:682\u2013700. https:\/\/doi.org\/10.1038\/s42255-021-00391-x.","DOI":"10.1038\/s42255-021-00391-x"},{"key":"255_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2024.117688","volume":"181","author":"J-H Chen","year":"2024","unstructured":"Chen J-H, Tu H-J, Lin TE, Peng Z-X, Wu Y-W, Yen S-C, et al (2024) Discovery of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors using an artificial intelligence model and their effects on tau and tubulin dynamics. Biomed Pharmacother. 181: 117688. https:\/\/doi.org\/10.1016\/J.BIOPHA.2024.117688.","journal-title":"Biomed Pharmacother"},{"key":"255_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147391","volume":"11","author":"STW Cheng","year":"2016","unstructured":"Cheng STW, Chen L, Li SYT, Mayoux E, Leung PS (2016) The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic \u03b2-cell mass and glucose homeostasis in type 1 diabetes. PLoS One. 11: 1\u201312. https:\/\/doi.org\/10.1371\/journal.pone.0147391.","journal-title":"PLoS One"},{"key":"255_CR39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2337\/DB22-0708","volume":"72","author":"E Chow","year":"2023","unstructured":"Chow E, Wang K, Lim CKP, Tsoi STF, Fan B, Poon E, et al (2023) Dorzagliatin, a dual-acting glucokinase activator, increases insulin secretion and glucose sensitivity in glucokinase maturity-onset diabetes of the young and recent-onset type 2 diabetes. Diabetes. 72:299\u2013308. https:\/\/doi.org\/10.2337\/DB22-0708.","journal-title":"Diabetes"},{"key":"255_CR40","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1002\/STEM.482","volume":"28","author":"C-H Chung","year":"2010","unstructured":"Chung C-H, Hao E, Piran R, Keinan E, Levine F (2010) Pancreatic \u03b2-cell neogenesis by direct conversion from mature \u03b1-cells. Stem Cells. 28:1630\u20138. https:\/\/doi.org\/10.1002\/STEM.482.","journal-title":"Stem Cells"},{"key":"255_CR41","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/S00592-024-02300-6","volume":"61","author":"S Ciardullo","year":"2024","unstructured":"Ciardullo S, Morieri ML, Daniele G, Fiorentino TV, Mezza T, Tric\u00f2 D, et al (2024) GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes. Acta Diabetol. 61:941\u201350. https:\/\/doi.org\/10.1007\/S00592-024-02300-6.","journal-title":"Acta Diabetol"},{"key":"255_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/J.MOLMET.2022.101582","volume":"65","author":"CJ Contreras","year":"2022","unstructured":"Contreras CJ, Mukherjee N, Branco RCS, Lin L, Hogan MF, Cai EP, et al (2022) RIPK1 and RIPK3 regulate TNF\u03b1-induced \u03b2-cell death in concert with caspase activity. Mol Metab. 65: 101582. https:\/\/doi.org\/10.1016\/J.MOLMET.2022.101582.","journal-title":"Mol Metab"},{"key":"255_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/J.MOLMET.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al (2018) LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 18:3\u201314. https:\/\/doi.org\/10.1016\/J.MOLMET.2018.09.009.","journal-title":"Mol Metab"},{"key":"255_CR44","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1111\/BCP.15182","volume":"88","author":"P Czarniak","year":"2022","unstructured":"Czarniak P, Ahmadizar F, Hughes J, Parsons R, Kavousi M, Ikram M, et al (2022) Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population-based cohort study. Br J Clin Pharmacol. 88:2718\u201326. https:\/\/doi.org\/10.1111\/BCP.15182.","journal-title":"Br J Clin Pharmacol"},{"key":"255_CR45","doi-asserted-by":"publisher","unstructured":"Dantas JR, Ara\u00fajo DB, Silva KR, Souto DL, de F\u00e1tima Carvalho Pereira M, Luiz RR, et al (2021) Adipose tissue-derived stromal\/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients. Arch Endocrinol Metab.65:342\u201351. https:\/\/doi.org\/10.20945\/2359-3997000000368,.","DOI":"10.20945\/2359-3997000000368"},{"key":"255_CR46","doi-asserted-by":"publisher","unstructured":"D\u2019Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, et al (2006) Production of pancreatic hormone\u2013expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 24:1392\u2013401. https:\/\/doi.org\/10.1038\/nbt1259.","DOI":"10.1038\/nbt1259"},{"key":"255_CR47","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.2337\/DB15-1127","volume":"65","author":"E Dirice","year":"2016","unstructured":"Dirice E, Walpita D, Vetere A, Meier BC, Kahraman S, Hu J, et al (2016a) Inhibition of DYRK1A stimulates human \u03b2-cell proliferation. Diabetes. 65:1660\u201371. https:\/\/doi.org\/10.2337\/DB15-1127.","journal-title":"Diabetes"},{"key":"255_CR48","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.2337\/DB15-1127\/-\/DC1","volume":"65","author":"E Dirice","year":"2016","unstructured":"Dirice E, Walpita D, Vetere A, Meier BC, Kahraman S, Hu J, et al (2016c)Inhibition of DYRK1A stimulates human \u03b2-cell proliferation. Diabetes. 65:1660\u201371. https:\/\/doi.org\/10.2337\/DB15-1127\/-\/DC1.","journal-title":"Diabetes"},{"key":"255_CR49","doi-asserted-by":"publisher","unstructured":"Dirnagl U, Duda GN, Grainger DW, Reinke P, Roubenoff R (2022) Reproducibility, relevance and reliability as barriers to efficient and credible biomedical technology translation. Adv Drug Deliv Rev.182. https:\/\/doi.org\/10.1016\/J.ADDR.2022.114118,.","DOI":"10.1016\/J.ADDR.2022.114118"},{"key":"255_CR50","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamasurg.2024.7082","volume":"94305","author":"AA Dixit","year":"2025","unstructured":"Dixit AA, Bateman BT, Hawn MT, Odden MC, Sun EC (2025) Preoperative SGLT2 Inhibitor Use and Postoperative Diabetic Ketoacidosis. JAMA Surg. 94305:423\u201330. https:\/\/doi.org\/10.1001\/jamasurg.2024.7082.","journal-title":"JAMA Surg"},{"key":"255_CR51","doi-asserted-by":"publisher","unstructured":"Docherty FM, Sussel L (2022) Islet Regeneration: Endogenous and Exogenous Approaches. Int J Mol Sci. 22:3306. https:\/\/doi.org\/10.3390\/IJMS22073306.","DOI":"10.3390\/IJMS22073306"},{"key":"255_CR52","doi-asserted-by":"publisher","unstructured":"Huang Dongxuan, Chen P, Huang G, Sun H, Luo X, He C, et al (2022) Salt-inducible kinases inhibitor HG-9\u201391\u201301 targets RIPK3 kinase activity to alleviate necroptosis-mediated inflammatory injury. Cell Death Dis. 13:1\u201314. https:\/\/doi.org\/10.1038\/s41419-022-04633-y.","DOI":"10.1038\/s41419-022-04633-y"},{"key":"255_CR53","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","volume":"113","author":"ME Doyle","year":"2007","unstructured":"Doyle ME, Egan JM (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 113:546\u201393. https:\/\/doi.org\/10.1016\/j.pharmthera.2006.11.007.","journal-title":"Pharmacol Ther"},{"key":"255_CR54","doi-asserted-by":"publisher","unstructured":"Eguchi N, Toribio AJ, Alexander M, Xu I, Whaley DL, Hernandez LF, et al (2022) Dysregulation of \u03b2-Cell Proliferation in Diabetes: Possibilities of Combination Therapy in the Development of a Comprehensive Treatment. Biomed. 10:472. https:\/\/doi.org\/10.3390\/BIOMEDICINES10020472.","DOI":"10.3390\/BIOMEDICINES10020472"},{"key":"255_CR55","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/rme-2021-0016","volume":"16","author":"CJ Esdaille","year":"2021","unstructured":"Esdaille CJ, Washington KS, Laurencin CT (2021) Regenerative engineering: A review of recent advances and future directions. Regen Med. 16:495\u2013512. https:\/\/doi.org\/10.2217\/rme-2021-0016.","journal-title":"Regen Med"},{"key":"255_CR56","doi-asserted-by":"publisher","first-page":"30707","DOI":"10.1074\/JBC.M702607200","volume":"282","author":"Y Fujinaka","year":"2007","unstructured":"Fujinaka Y, Takane K, Yamashita H, Vasavada RC (2007) Lactogens Promote Beta Cell Survival through JAK2\/STAT5 Activation and Bcl-XL Upregulation. J Biol Chem. 282:30707\u201317. https:\/\/doi.org\/10.1074\/JBC.M702607200.","journal-title":"J Biol Chem"},{"key":"255_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-017-09898-4","author":"J Fusco","year":"2017","unstructured":"Fusco J, Xiao X, Prasadan K, Sheng Q, Chen C, Ming YC, et al (2017b) GLP-1\/Exendin-4 induces \u03b2-cell proliferation via the epidermal growth factor receptor. Sci Rep. . https:\/\/doi.org\/10.1038\/S41598-017-09898-4.","journal-title":"Sci Rep"},{"key":"255_CR58","doi-asserted-by":"publisher","unstructured":"Fusco J, Xiao X, Prasadan K, Sheng Q, Chen C, Ming YC, et al (2017a) GLP-1\/Exendin-4 induces \u03b2-cell proliferation via the epidermal growth factor receptor. Sci Rep 7. https:\/\/doi.org\/10.1038\/s41598-017-09898-4.","DOI":"10.1038\/s41598-017-09898-4"},{"key":"255_CR59","doi-asserted-by":"publisher","first-page":"1004044","DOI":"10.3389\/FENDO.2022.1004044\/BIBTEX","volume":"13","author":"B Gallwitz","year":"2022","unstructured":"Gallwitz B (2022) Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Front Endocrinol (Lausanne). 13:1004044. https:\/\/doi.org\/10.3389\/FENDO.2022.1004044\/BIBTEX.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"255_CR60","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/J.DEVCEL.2022.01.012","volume":"57","author":"JC Garbern","year":"2022","unstructured":"Garbern JC, Lee RT (2022) Heart regeneration: 20 years of progress and renewed optimism. Dev Cell. 57:424\u201339. https:\/\/doi.org\/10.1016\/J.DEVCEL.2022.01.012.","journal-title":"Dev Cell"},{"key":"255_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/ENDOCR\/BQAC193","volume":"164","author":"RA Goode","year":"2022","unstructured":"Goode RA, Hum JM, Kalwat MA (2022) Therapeutic strategies targeting pancreatic islet \u03b2-cell proliferation, regeneration, and replacement. Endocrinology. 164:1\u201320. https:\/\/doi.org\/10.1210\/ENDOCR\/BQAC193.","journal-title":"Endocrinology"},{"key":"255_CR62","doi-asserted-by":"publisher","unstructured":"Guo Y\u202f;, Li L\u202f;, Yao Y\u202f;, Li H, Guo Yichuan, Li Lingqiao, et al (2022) Citation: Regeneration of Pancreatic \u03b2-Cells for Diabetes Therapeutics by Natural DYRK1A Inhibitors. https:\/\/doi.org\/10.3390\/metabo13010051.","DOI":"10.3390\/metabo13010051"},{"key":"255_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2022.972115","volume":"13","author":"DW Hagan","year":"2022","unstructured":"Hagan DW, Ferreira SM, Santos GJ, Phelps EA (2022) The role of GABA in islet function. Front Endocrinol (Lausanne). 13:1\u201318. https:\/\/doi.org\/10.3389\/fendo.2022.972115.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"255_CR64","doi-asserted-by":"publisher","unstructured":"Hamad FRB, Rahat N, Shankar K, Tsouklidis N (2021) Efficacy of Stem Cell Application in Diabetes Mellitus: Promising Future Therapy for Diabetes and Its Complications. Cureus 13. https:\/\/doi.org\/10.7759\/CUREUS.13563.","DOI":"10.7759\/CUREUS.13563"},{"key":"255_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02165-4","author":"SMR Hashemian","year":"2021","unstructured":"Hashemian SMR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini SE, et al (2021) Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. https:\/\/doi.org\/10.1186\/s13287-021-02165-4.","journal-title":"Stem Cell Res Ther"},{"key":"255_CR66","doi-asserted-by":"publisher","DOI":"10.2337\/DB18-138-OR","author":"RR Henry","year":"2018","unstructured":"Henry RR, Pettus J, Wilensky J, Shapiro AMJ, Senior PA, Roep B, et al (2018) Initial clinical evaluation of VC-01TM combination product\u2014a stem cell\u2013derived islet replacement for type 1 diabetes (T1D). Diabetes. https:\/\/doi.org\/10.2337\/DB18-138-OR.","journal-title":"Diabetes"},{"key":"255_CR67","doi-asserted-by":"publisher","DOI":"10.2337\/db25-0037","author":"BJ Hering","year":"2025","unstructured":"Hering BJ, Rickels MR, Bellin MD, Millman JR, Tomei AA, Garc\u00eda AJ, et al (2025) Advances in cell replacement therapies for diabetes. Diabetes. https:\/\/doi.org\/10.2337\/db25-0037.","journal-title":"Diabetes"},{"key":"255_CR68","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","volume":"9","author":"M von Herrath","year":"2021","unstructured":"von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, et al (2021) Anti-interleukin-21 antibody and liraglutide for the preservation of \u03b2-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol.9:212\u201324. https:\/\/doi.org\/10.1016\/S2213-8587(21)00019-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"255_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.498758","volume":"11","author":"F Heydarpour","year":"2020","unstructured":"Heydarpour F, Sajadimajd S, Mirzarazi E, Haratipour P, Joshi T, Farzaei MH, et al (2020) Involvement of TGF-\u03b2 and autophagy pathways in pathogenesis of diabetes: a comprehensive review on biological and pharmacological insights. Front Pharmacol. 11:1\u201321. https:\/\/doi.org\/10.3389\/fphar.2020.498758.","journal-title":"Front Pharmacol"},{"key":"255_CR70","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/J.METABOL.2019.04.014","volume":"96","author":"JJ Holst","year":"2019","unstructured":"Holst JJ (2019) The incretin system in healthy humans: the role of GIP and GLP-1. Metabolism. 96:46\u201355. https:\/\/doi.org\/10.1016\/J.METABOL.2019.04.014.","journal-title":"Metabolism"},{"key":"255_CR71","doi-asserted-by":"publisher","unstructured":"Hora S, Wuestefeld T (2023) Liver Injury and Regeneration: Current Understanding, New Approaches, and Future Perspectives. Cells. 12. https:\/\/doi.org\/10.3390\/cells12172129.","DOI":"10.3390\/cells12172129"},{"key":"255_CR72","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/B978-0-12-800101-1.00010-7","volume":"121","author":"Y Huang","year":"2014","unstructured":"Huang Y, Chang Y (2014) Regulation of pancreatic islet beta-cell mass by growth factor and hormone signaling. Prog Mol Biol Transl Sci. 121:321\u201349. https:\/\/doi.org\/10.1016\/B978-0-12-800101-1.00010-7.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"255_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-023-01816-5","volume":"22","author":"K Huang","year":"2023","unstructured":"Huang K, Luo X, Liao B, Li G, Feng J (2023) Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. Cardiovasc Diabetol. 22:1\u201323. https:\/\/doi.org\/10.1186\/s12933-023-01816-5.","journal-title":"Cardiovasc Diabetol"},{"key":"255_CR74","doi-asserted-by":"publisher","first-page":"7747","DOI":"10.1128\/MCB.02353-05","volume":"26","author":"MA Hussain","year":"2006","unstructured":"Hussain MA, Porras DL, Rowe MH, West JR, Song W-J, Schreiber WE, et al (2006) Increased pancreatic \u03b2-cell proliferation mediated by CREB binding protein gene activation. Mol Cell Biol. 26:7747\u201359. https:\/\/doi.org\/10.1128\/MCB.02353-05.","journal-title":"Mol Cell Biol"},{"key":"255_CR75","doi-asserted-by":"publisher","unstructured":"Iakovleva V, Wuestefeld A, Ong ABL, Gao R, Kaya NA, Lee MY, et al (2023) Mfap4: a promising target for enhanced liver regeneration and chronic liver disease treatment. Npj Regen Med. 8:1\u201317. https:\/\/doi.org\/10.1038\/s41536-023-00337-9.","DOI":"10.1038\/s41536-023-00337-9"},{"key":"255_CR76","unstructured":"H\u00fc SR, White MF, Rhodes CJ (1998) Insulin-like Growth Factor I (IGF-I)-stimulated Pancreatic-Cell Growth Is Glucose-dependent synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and igf-i in ins-1 cells."},{"key":"255_CR77","doi-asserted-by":"publisher","unstructured":"Iorio C, Rourke JL, Wells L, Sakamaki JI, Moon E, Hu Q, et al (2021) Silencing the G-protein coupled receptor 3-salt inducible kinase 2 pathway promotes human \u03b2 cell proliferation. Commun Biol. 4:1\u201313. https:\/\/doi.org\/10.1038\/s42003-021-02433-2.","DOI":"10.1038\/s42003-021-02433-2"},{"key":"255_CR78","doi-asserted-by":"publisher","unstructured":"Izadi M, Sadr Hashemi Nejad A, Moazenchi M, Masoumi S, Rabbani A, Kompani F, et al (2022) Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I\/II randomized placebo-controlled clinical trial. Stem Cell Res Ther.13. https:\/\/doi.org\/10.1186\/S13287-022-02941-W,.","DOI":"10.1186\/S13287-022-02941-W"},{"key":"255_CR79","doi-asserted-by":"publisher","first-page":"9791","DOI":"10.1021\/ACS.JMEDCHEM.8B00185\/ASSET\/IMAGES\/MEDIUM\/JM-2018-00185V_0026.GIF","volume":"61","author":"DB Jarhad","year":"2018","unstructured":"Jarhad DB, Mashelkar KK, Kim HR, Noh M, Jeong LS (2018) Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics. J Med Chem. 61:9791\u2013810. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.8B00185\/ASSET\/IMAGES\/MEDIUM\/JM-2018-00185V_0026.GIF.","journal-title":"J Med Chem"},{"key":"255_CR80","doi-asserted-by":"publisher","unstructured":"Ji Z, Lu M, Xie H, Yuan H, Chen Q (2022) \u03b2 cell regeneration and novel strategies for treatment of diabetes (Review). Biomed Reports. 17. https:\/\/doi.org\/10.3892\/br.2022.1555.","DOI":"10.3892\/br.2022.1555"},{"key":"255_CR81","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a014084","author":"SK Karathanasis","year":"2014","unstructured":"Karathanasis SK. Regenerative medicine: transforming the drug discovery and development paradigm. Cold Spring Harb Perspect Med. 2014. https:\/\/doi.org\/10.1101\/cshperspect.a014084.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"255_CR82","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/08820139.2023.2289066","volume":"53","author":"F Karimi","year":"2024","unstructured":"Karimi F, Nejati B, Rahimi F, Alivirdiloo V, Alipourfard I, Aghighi A, et al (2024) A state-of-the-art review on the recent advances of mesenchymal stem cell therapeutic application in systematic lupus erythematosus. Immunol Invest. 53:160\u201384. https:\/\/doi.org\/10.1080\/08820139.2023.2289066.","journal-title":"Immunol Invest"},{"key":"255_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES10020203","author":"D Karlsson","year":"2022","unstructured":"Karlsson D, Ahnmark A, Sabirsh A, Andr\u00e9asson AC, Gennemark P, Sandinge AS, et al (2022) Inhibition of SGLT2 preserves function and promotes proliferation of human islets cells in vivo in diabetic mice. Biomedicines. https:\/\/doi.org\/10.3390\/BIOMEDICINES10020203.","journal-title":"Biomedicines"},{"key":"255_CR84","doi-asserted-by":"publisher","unstructured":"Khan I, Neumann C, Sinha M (2020) Tissue regeneration and reprogramming. Wound Heal Tissue Repair, Regen Diabetes.515\u201334. https:\/\/doi.org\/10.1016\/B978-0-12-816413-6.00024-1.","DOI":"10.1016\/B978-0-12-816413-6.00024-1"},{"key":"255_CR85","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/J.COPH.2021.05.002","volume":"59","author":"PPPSJ Khedoe","year":"2021","unstructured":"Khedoe PPPSJ, Wu X, Gosens R, Hiemstra PS (2021) Repairing damaged lungs using regenerative therapy. Curr Opin Pharmacol. 59:85\u201394. https:\/\/doi.org\/10.1016\/J.COPH.2021.05.002.","journal-title":"Curr Opin Pharmacol"},{"key":"255_CR86","doi-asserted-by":"publisher","unstructured":"Kholodenko I V., Yarygin KN (2017) Cellular Mechanisms of Liver Regeneration and Cell-Based Therapies of Liver Diseases. Biomed Res Int. https:\/\/doi.org\/10.1155\/2017\/8910821.","DOI":"10.1155\/2017\/8910821"},{"key":"255_CR87","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1124\/pr.108.000604","volume":"60","author":"W Kim","year":"2008","unstructured":"Kim W, Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 60:470\u2013512. https:\/\/doi.org\/10.1124\/pr.108.000604.","journal-title":"Pharmacol Rev"},{"key":"255_CR88","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1124\/DMD.113.055616","volume":"42","author":"AH Kim","year":"2014","unstructured":"Kim AH, Chung I, Yoon SH, Yu KS, Lim KS, Cho JY, et al (2014) Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab Dispos. 42:1174\u20139. https:\/\/doi.org\/10.1124\/DMD.113.055616.","journal-title":"Drug Metab Dispos"},{"key":"255_CR89","doi-asserted-by":"publisher","unstructured":"Kim H, Toyofuku Y, Lynn FC, Chak E, Uchida T, Mizukami H, et al (2010) Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med. 16:804\u20138. https:\/\/doi.org\/10.1038\/nm.2173.","DOI":"10.1038\/nm.2173"},{"key":"255_CR90","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2337\/DC20-2684","volume":"44","author":"KR Klein","year":"2021","unstructured":"Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, Buse JB, et al (2021) The SimpliciT1 study: a randomized, double-blind, placebo-controlled phase 1b\/2 adaptive study of TTP399, a hepatoselective glucokinase activator, for adjunctive treatment of type 1 diabetes. Diabetes Care. 44:960\u20138. https:\/\/doi.org\/10.2337\/DC20-2684.","journal-title":"Diabetes Care"},{"key":"255_CR91","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/DOM.14697","volume":"24","author":"KR Klein","year":"2022","unstructured":"Klein KR, Boeder SC, Freeman JLR, Dunn I, Dvergsten C, Madduri S, et al (2022) Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes. Diabetes, Obes Metab. 24:1439\u201347. https:\/\/doi.org\/10.1111\/DOM.14697.","journal-title":"Diabetes, Obes Metab"},{"key":"255_CR92","doi-asserted-by":"publisher","unstructured":"Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402:705\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(23)01185-6.","DOI":"10.1016\/S0140-6736(23)01185-6"},{"key":"255_CR93","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/J.CMET.2015.05.021","volume":"22","author":"NG Kondegowda","year":"2015","unstructured":"Kondegowda NG, Fenutria R, Pollack IR, Orthofer M, Garcia-Oca\u00f1a A, Penninger JM, et al (2015) Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-\u03baB Ligand (RANKL) Pathway. Cell Metab. 22:77. https:\/\/doi.org\/10.1016\/J.CMET.2015.05.021.","journal-title":"Cell Metab"},{"key":"255_CR94","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ebiom.2018.03.014","volume":"30","author":"SV Korol","year":"2018","unstructured":"Korol SV, Jin Z, Jin Y, Bhandage AK, Tengholm A, Gandasi NR, et al (2018) Functional characterization of native, high-affinity GABAA receptors in human pancreatic \u03b2 cells. EBioMedicine. 30:273\u201382. https:\/\/doi.org\/10.1016\/j.ebiom.2018.03.014.","journal-title":"EBioMedicine"},{"key":"255_CR95","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/bjc.2014.286","volume":"111","author":"J Kraan","year":"2014","unstructured":"Kraan J, Van Den Broek P, Verhoef C, Grunhagen DJ, Taal W, Gratama JW, et al (2014) Endothelial CD276 (B7\u2013H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells. Br J Cancer. 111:149\u201356. https:\/\/doi.org\/10.1038\/bjc.2014.286.","journal-title":"Br J Cancer"},{"key":"255_CR96","doi-asserted-by":"publisher","unstructured":"Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, et al (2008) Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008 264 26:443\u201352. https:\/\/doi.org\/10.1038\/nbt1393.","DOI":"10.1038\/nbt1393"},{"key":"255_CR97","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1021\/ACS.JMEDCHEM.9B01379","volume":"63","author":"K Kumar","year":"2020","unstructured":"Kumar K, Wang P, Wilson J, Zlatanic V, Berrouet C, Khamrui S, et al (2020) Synthesis and Biological Validation of a Harmine-based, Central Nervous System (CNS)-Avoidant, Selective, Human \u03b2-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor. J Med Chem. 63:2986. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.9B01379.","journal-title":"J Med Chem"},{"key":"255_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.3820.Induction","volume":"2","author":"AR Kwilas","year":"2015","unstructured":"Kwilas AR, Donahue RN, Tsang KY, Hodge JW (2015) \u4e73\u9f20\u5fc3\u808c\u63d0\u53d6 HHS Public Access. Cancer Cell. 2:1\u201317. https:\/\/doi.org\/10.1038\/nm.3820.Induction.","journal-title":"Cancer Cell"},{"key":"255_CR99","doi-asserted-by":"publisher","unstructured":"Lagunas-Rangel FA, Koshelev D, Nedorubov A, Kosheleva L, Trukhan V, Rabinovitch A, et al (2022) Triple drug therapy with GABA, sitagliptin, and omeprazole prevents type 1 diabetes onset and promotes its reversal in non-obese diabetic mice. Front Endocrinol (Lausanne) 13. https:\/\/doi.org\/10.3389\/FENDO.2022.1028114.","DOI":"10.3389\/FENDO.2022.1028114"},{"key":"255_CR100","doi-asserted-by":"publisher","unstructured":"Lee YN, Yi HJ, Seo EH, Oh J, Lee S, Ferber S, et al (2021) Improvement of the therapeutic capacity of insulin-producing cells trans-differentiated from human liver cells using engineered cell sheet. Stem Cell Res Ther 12. https:\/\/doi.org\/10.1186\/S13287-020-02080-0.","DOI":"10.1186\/S13287-020-02080-0"},{"issue":"7","key":"255_CR101","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/cdd.2014.193","volume":"22","author":"M Lemper","year":"2015","unstructured":"Lemper M, Leuckx G, Heremans Y, German MS, Heimberg H, Bouwens L, et al (2015) Reprogramming of human pancreatic exocrine cells to \u03b2-like cells. Cell Death Differ. 22(7):1117\u201330. https:\/\/doi.org\/10.1038\/cdd.2014.193.","journal-title":"Cell Death Differ"},{"issue":"2","key":"255_CR102","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4158\/EP12138.RA","volume":"19","author":"CS Levetan","year":"2013","unstructured":"Levetan CS, Pierce SM (2013) Distinctions between the islets of mice and men: Implications for new therapies for type 1 and 2 diabetes. Endocr Pract. 19(2):301\u201312. https:\/\/doi.org\/10.4158\/EP12138.RA.","journal-title":"Endocr Pract"},{"key":"255_CR103","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/J.CELL.2016.11.010","volume":"168","author":"J Li","year":"2017","unstructured":"Li J, Casteels T, Huber KVM, Lardeau CH, Klughammer J, Farlik M, et al (2017) Artemisinins target GABAA receptor signaling and impair \u03b1 cell identity. Cell. 168:86-100.e15. https:\/\/doi.org\/10.1016\/J.CELL.2016.11.010.","journal-title":"Cell"},{"key":"255_CR104","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021429","volume":"99","author":"B Liang","year":"2020","unstructured":"Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al (2020) Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine. 99: E21429. https:\/\/doi.org\/10.1097\/MD.0000000000021429.","journal-title":"Medicine"},{"key":"255_CR105","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/FENDO.2024.1431292\/BIBTEX","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK (2024) Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 15:1431292. https:\/\/doi.org\/10.3389\/FENDO.2024.1431292\/BIBTEX.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"255_CR106","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/CMDC.202000183","volume":"15","author":"YA Liu","year":"2020","unstructured":"Liu YA, Jin Q, Ding Q, Hao X, Mo T, Yan S, et al (2020a) A dual inhibitor of DYRK1A and GSK3\u03b2 for \u03b2-cell proliferation: aminopyrazine derivative GNF4877. ChemMedChem.15:1562\u201370. https:\/\/doi.org\/10.1002\/CMDC.202000183.","journal-title":"ChemMedChem"},{"key":"255_CR107","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1021\/ACS.JMEDCHEM.9B01624","volume":"63","author":"YA Liu","year":"2020","unstructured":"Liu YA, Jin Q, Zou Y, Ding Q, Yan S, Wang Z, et al (2020b) Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133. J Med Chem.63:2958\u201373. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.9B01624.","journal-title":"J Med Chem"},{"key":"255_CR108","doi-asserted-by":"publisher","unstructured":"Lu J, Shen S mei, Ling Q, Wang B, Li L rong, Zhang W, et al (2021) One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study. Stem Cell Res Ther. 12. https:\/\/doi.org\/10.1186\/S13287-021-02417-3,.","DOI":"10.1186\/S13287-021-02417-3"},{"key":"255_CR109","doi-asserted-by":"publisher","unstructured":"M. Kim CT (2004) \u57fa\u56e0\u7684\u6539\u53d8NIH Public Access. Brain Lang.88:1\u201320. https:\/\/doi.org\/10.1038\/ncb2919.Role.","DOI":"10.1038\/ncb2919.Role"},{"key":"255_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2023.110247","volume":"119","author":"Y Ma","year":"2023","unstructured":"Ma Y, Lang X, Yang Q, Han Y, Kang X, Long R, et al (2023) Paeoniflorin promotes intestinal stem cell-mediated epithelial regeneration and repair via PI3K-AKT-mTOR signalling in ulcerative colitis. Int Immunopharmacol. 119: 110247. https:\/\/doi.org\/10.1016\/J.INTIMP.2023.110247.","journal-title":"Int Immunopharmacol"},{"key":"255_CR111","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/cr.2017.84","volume":"27","author":"A Magadum","year":"2017","unstructured":"Magadum A, Ding Y, He L, Kim T, Vasudevarao MD, Long Q, et al (2017) Live cell screening platform identifies PPAR\u03b4 as a regulator of cardiomyocyte proliferation and cardiac repair. Cell Res. 27:1002\u201319. https:\/\/doi.org\/10.1038\/cr.2017.84.","journal-title":"Cell Res"},{"key":"255_CR112","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.119.043067","volume":"141","author":"A Magadum","year":"2020","unstructured":"Magadum A, Singh N, Kurian AA, Munir I, Mehmood T, Brown K, et al (2020) Pkm2 regulates cardiomyocyte cell cycle and promotes cardiac regeneration. Circulation. 141:1249. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.043067.","journal-title":"Circulation"},{"key":"255_CR113","doi-asserted-by":"publisher","first-page":"14452","DOI":"10.1073\/PNAS.1508520112\/ASSET\/25962D2F-8773-4F25-94E0-B24854C67360\/ASSETS\/GRAPHIC\/PNAS.1508520112FIG03.JPEG","volume":"112","author":"AS Mao","year":"2015","unstructured":"Mao AS, Mooney DJ (2015) Regenerative medicine: Current therapies and future directions. Proc Natl Acad Sci U S A. 112:14452\u20139. https:\/\/doi.org\/10.1073\/PNAS.1508520112\/ASSET\/25962D2F-8773-4F25-94E0-B24854C67360\/ASSETS\/GRAPHIC\/PNAS.1508520112FIG03.JPEG.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"255_CR114","doi-asserted-by":"publisher","unstructured":"Matschinsky FM, Zelent B, Doliba N, Li C, Vanderkooi JM, Naji A, et al (2011) Glucokinase activators for diabetes therapy: May 2010 status report. Diabetes Care. 34. https:\/\/doi.org\/10.2337\/dc11-s236.","DOI":"10.2337\/dc11-s236"},{"key":"255_CR115","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/01.ogx.0000219511.20627.d3","volume":"61","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al (2006) Denosumab in postmenopausal women with low bone mineral density: Commentary. Obstet Gynecol Surv. 61:384\u20136. https:\/\/doi.org\/10.1097\/01.ogx.0000219511.20627.d3.","journal-title":"Obstet Gynecol Surv"},{"key":"255_CR116","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/J.BEEM.2015.10.006","volume":"29","author":"I Meivar-Levy","year":"2015","unstructured":"Meivar-Levy I, Ferber S (2015) Reprogramming of liver cells into insulin-producing cells. Best Pract Res Clin Endocrinol Metab.29:873\u201382. https:\/\/doi.org\/10.1016\/J.BEEM.2015.10.006.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"255_CR117","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2337\/DB07-1294","volume":"57","author":"BA Menge","year":"2008","unstructured":"Menge BA, Tannapfel A, Belyaev O, Drescher R, M\u00fcller C, Uhl W, et al (2008) Partial pancreatectomy in adult humans does not provoke \u03b2-cell regeneration. Diabetes. 57:142\u20139. https:\/\/doi.org\/10.2337\/DB07-1294.","journal-title":"Diabetes"},{"key":"255_CR118","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/8755122518790925","volume":"34","author":"KE Miles","year":"2018","unstructured":"Miles KE, Kerr JL (2018) Semaglutide for the Treatment of Type 2 Diabetes Mellitus. J Pharm Technol. 34:281. https:\/\/doi.org\/10.1177\/8755122518790925.","journal-title":"J Pharm Technol"},{"key":"255_CR119","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/J.CELL.2018.02.014","volume":"173","author":"TMA Mohamed","year":"2018","unstructured":"Mohamed TMA, Ang YS, Radzinsky E, Zhou P, Huang Y, Elfenbein A, et al (2018) Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration. Cell. 173:104. https:\/\/doi.org\/10.1016\/J.CELL.2018.02.014.","journal-title":"Cell"},{"key":"255_CR120","doi-asserted-by":"publisher","unstructured":"Morace C, Lorello G, Bellone F, Quartarone C, Ruggeri D, Giandalia A, et al (2024) Ketoacidosis and SGLT2 Inhibitors: A Narrative Review. Metabolites.14. https:\/\/doi.org\/10.3390\/metabo14050264.","DOI":"10.3390\/metabo14050264"},{"key":"255_CR121","doi-asserted-by":"publisher","unstructured":"Muruganandan S, Wigerius M. Novel (2020) Targets and Therapeutic Strategies for Promoting Organ Repair and Regeneration. Biomol.10:749. https:\/\/doi.org\/10.3390\/BIOM10050749.","DOI":"10.3390\/BIOM10050749"},{"key":"255_CR122","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/J.EURONEURO.2015.03.018","volume":"25","author":"G Naert","year":"2015","unstructured":"Naert G, Ferr\u00e9 V, Meunier J, Keller E, Malmstr\u00f6m S, Givalois L, et al (2015) Leucettine L41, a DYRK1A-preferential DYRKs\/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric A\u03b225\u201335 peptide administration in mice. Eur Neuropsychopharmacol. 25:2170\u201382. https:\/\/doi.org\/10.1016\/J.EURONEURO.2015.03.018.","journal-title":"Eur Neuropsychopharmacol"},{"key":"255_CR123","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","volume":"9","author":"IJ Neeland","year":"2021","unstructured":"Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, et al (2021) Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 9:595\u2013605. https:\/\/doi.org\/10.1016\/S2213-8587(21)00179-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"255_CR124","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/13543776.2017.1360285","volume":"27","author":"TL Nguyen","year":"2017","unstructured":"Nguyen TL, Fruit C, H\u00e9rault Y, Meijer L, Besson T (2017) Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature. Expert Opin Ther Pat.27:1183\u201399. https:\/\/doi.org\/10.1080\/13543776.2017.1360285.","journal-title":"Expert Opin Ther Pat"},{"key":"255_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.medntd.2023.100247","author":"OA Ojo","year":"2023","unstructured":"Ojo OA, Sokolayam Ibrahim H, Rotimi E, Daniel Ogunlakin A, Ojo B (2023) Diabetes Mellitus: from Molecular Mechanism to Pathophysiology and Pharmacology. https:\/\/doi.org\/10.1016\/j.medntd.2023.100247.","journal-title":"Diabetes Mellitus: from Molecular Mechanism to Pathophysiology and Pharmacology"},{"key":"255_CR126","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.cmet.2015.12.001","volume":"23","author":"A El Ouaamari","year":"2016","unstructured":"El Ouaamari A, Dirice E, Gedeon N, Hu J, Zhou JY, Shirakawa J, et al (2016) SerpinB1 promotes pancreatic \u03b2 cell proliferation. Cell Metab. 23:194\u2013205. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.001.","journal-title":"Cell Metab"},{"key":"255_CR127","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/J.CELL.2014.09.040\/ATTACHMENT\/315FD9CF-344E-4664-8924-EF3AF313DDC5\/MMC4.PDF","volume":"159","author":"FW Pagliuca","year":"2014","unstructured":"Pagliuca FW, Millman JR, G\u00fcrtler M, Segel M, Van Dervort A, Ryu JH, et al (2014) Generation of functional human pancreatic \u03b2 cells in vitro. Cell. 159:428\u201339. https:\/\/doi.org\/10.1016\/J.CELL.2014.09.040\/ATTACHMENT\/315FD9CF-344E-4664-8924-EF3AF313DDC5\/MMC4.PDF.","journal-title":"Cell"},{"key":"255_CR128","doi-asserted-by":"publisher","first-page":"7806435","DOI":"10.1155\/2018\/7806435","volume":"2018","author":"BY Peng","year":"2018","unstructured":"Peng BY, Dubey NK, Mishra VK, Tsai FC, Dubey R, Deng WP, et al (2018) Addressing Stem Cell Therapeutic Approaches in Pathobiology of Diabetes and Its Complications. J Diabetes Res. 7806435. https:\/\/doi.org\/10.1155\/2018\/7806435.","journal-title":"J Diabetes Res"},{"key":"255_CR129","doi-asserted-by":"publisher","unstructured":"Piran R, Lee SH, Kuss P, Hao E, Newlin R, Mill\u00e1n JL, et al (2016) PAR2 regulates regeneration, transdifferentiation, and death. Cell Death Dis. 7:e2452\u2013e2452. https:\/\/doi.org\/10.1038\/cddis.2016.357.","DOI":"10.1038\/cddis.2016.357"},{"key":"255_CR130","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cmet.2011.02.012","volume":"13","author":"S Porat","year":"2011","unstructured":"Porat S, Weinberg-Corem N, Tornovsky-Babaey S, Schyr-Ben-Haroush R, Hija A, Stolovich-Rain M, et al (2011) Control of pancreatic \u03b2 cell regeneration by glucose metabolism. Cell Metab.13:440\u20139. https:\/\/doi.org\/10.1016\/j.cmet.2011.02.012.","journal-title":"Cell Metab"},{"key":"255_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22169083","author":"B Pucelik","year":"2021","unstructured":"Pucelik B, Barzowska A, D\u0105browski JM, Czarna A (2021) Diabetic kinome inhibitors\u2014a new opportunity for \u03b2-cells restoration. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22169083.","journal-title":"Int J Mol Sci"},{"key":"255_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285208","volume":"18","author":"B Pucelik","year":"2023","unstructured":"Pucelik B, Barzowska A, Czarna A (2023) DYRK1A inhibitors leucettines and TGF-\u03b2 inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets. PLoS One. 18: e0285208. https:\/\/doi.org\/10.1371\/journal.pone.0285208.","journal-title":"PLoS One"},{"key":"255_CR133","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.2337\/db14-0153","volume":"63","author":"I Purwana","year":"2014","unstructured":"Purwana I, Zheng J, Li X, Deurloo M, Son DO, Zhang Z, et al (2014a) GABA promotes human \u03b2-cell proliferation and modulates glucose homeostasis. Diabetes. 63:4197\u2013205. https:\/\/doi.org\/10.2337\/db14-0153.","journal-title":"Diabetes"},{"key":"255_CR134","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.stem.2021.10.003","volume":"28","author":"A Ramzy","year":"2021","unstructured":"Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, et al (2021) Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell. 28:2047-2061.e5. https:\/\/doi.org\/10.1016\/j.stem.2021.10.003.","journal-title":"Cell Stem Cell"},{"key":"255_CR135","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1210\/ENDREV\/BNAC021","volume":"44","author":"A Ramzy","year":"2023","unstructured":"Ramzy A, Belmonte PJ, Braam MJS, Ida S, Wilts EM, Levings MK, et al (2023) A century-long journey from the discovery of insulin to the implantation of stem cell\u2013derived islets. Endocr Rev. 44:222\u201353. https:\/\/doi.org\/10.1210\/ENDREV\/BNAC021.","journal-title":"Endocr Rev"},{"key":"255_CR136","doi-asserted-by":"publisher","unstructured":"Rezania A, Bruin JE, Xu J, Narayan K, Fox JK, O\u2019Neil JJ, et al (2013) Enrichment of human embryonic stem cell-derived NKX6.1-Expressing pancreatic progenitor cells accelerates the maturation of insulin-secreting cells in vivo. Stem Cells.31:2432\u201342. https:\/\/doi.org\/10.1002\/STEM.1489,.","DOI":"10.1002\/STEM.1489"},{"key":"255_CR137","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2147\/DMSO.S351982","volume":"15","author":"AA Rizvi","year":"2022","unstructured":"Rizvi AA, Rizzo M (2022) The emerging role of dual GLP-1 and GIP receptor agonists in glycemic management and cardiovascular risk reduction. Diabetes Metab Syndr Obes.15:1023\u201330. https:\/\/doi.org\/10.2147\/DMSO.S351982.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"255_CR138","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1161\/CIRCRESAHA.116.305374","volume":"116","author":"T Sadahiro","year":"2015","unstructured":"Sadahiro T, Yamanaka S, Ieda M (2015) Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications. Circ Res. 116:1378\u201391. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.305374.","journal-title":"Circ Res"},{"key":"255_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diseases8020014","volume":"8","author":"Y Saisho","year":"2020","unstructured":"Saisho Y (2020) SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 8:1\u201312. https:\/\/doi.org\/10.3390\/diseases8020014.","journal-title":"Diseases"},{"key":"255_CR140","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2337\/DC12-0421\/-\/DC1","volume":"36","author":"Y Saisho","year":"2013","unstructured":"Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC (2013) \u03b2-Cell mass and turnover in humans: Effects of obesity and aging. Diabetes Care. 36:111\u20137. https:\/\/doi.org\/10.2337\/DC12-0421\/-\/DC1.","journal-title":"Diabetes Care"},{"key":"255_CR141","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1042\/BST20210244","volume":"49","author":"M Saleh","year":"2021","unstructured":"Saleh M, Gittes GK, Prasadan K (2021) Alpha-to-beta cell trans-differentiation for treatment of diabetes. Biochem Soc Trans.49:2539\u201348. https:\/\/doi.org\/10.1042\/BST20210244.","journal-title":"Biochem Soc Trans"},{"key":"255_CR142","doi-asserted-by":"publisher","unstructured":"Sali S, Azzam L, Jaro T, Ali AAG, Mardini A, Al-Dajani O, et al (2025) A perfect islet: reviewing recent protocol developments and proposing strategies for stem cell derived functional pancreatic islets. Stem Cell Res Ther 16. https:\/\/doi.org\/10.1186\/s13287-025-04293-7.","DOI":"10.1186\/s13287-025-04293-7"},{"key":"255_CR143","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1124\/pharmrev.120.000160","volume":"73","author":"LS Satin","year":"2021","unstructured":"Satin LS, Soleimanpour SA, Walker EM (2021) New aspects of diabetes research and therapeutic development. Pharmacol Rev.73:1001\u201315. https:\/\/doi.org\/10.1124\/pharmrev.120.000160.","journal-title":"Pharmacol Rev"},{"key":"255_CR144","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/J.IMLET.2014.05.003","volume":"161","author":"L Shao","year":"2014","unstructured":"Shao L, Zhang P, Zhang Y, Ma A (2014) Inflammatory unbalance of TLR3 and TLR4 in PCI patients with or without type 2 diabetes mellitus. Immunol Lett. 161:81\u20138. https:\/\/doi.org\/10.1016\/J.IMLET.2014.05.003.","journal-title":"Immunol Lett"},{"key":"255_CR145","doi-asserted-by":"publisher","unstructured":"Shapiro AMJ, Thompson D, Donner TW, Bellin MD, Hsueh W, Pettus J, et al (2021) Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Med. 2. https:\/\/doi.org\/10.1016\/J.XCRM.2021.100466,.","DOI":"10.1016\/J.XCRM.2021.100466"},{"key":"255_CR146","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/JA309304M\/SUPPL_FILE\/JA309304M_SI_001.PDF","volume":"135","author":"W Shen","year":"2013","unstructured":"Shen W, Tremblay MS, Deshmukh VA, Wang W, Filippi CM, Harb G, et al (2013) Small-molecule inducer of \u03b2 cell proliferation identified by high-throughput screening. J Am Chem Soc. 135:1669\u201372. https:\/\/doi.org\/10.1021\/JA309304M\/SUPPL_FILE\/JA309304M_SI_001.PDF.","journal-title":"J Am Chem Soc"},{"key":"255_CR147","doi-asserted-by":"publisher","unstructured":"Shen W, Taylor B, Jin Q, Nguyen-Tran V, Meeusen S, Zhang YQ, et al (2015a) Inhibition of DYRK1A and GSK3B induces human \u03b2-cell proliferation. Nat Commun 6. https:\/\/doi.org\/10.1038\/ncomms9372.","DOI":"10.1038\/ncomms9372"},{"key":"255_CR148","doi-asserted-by":"publisher","unstructured":"Shen W, Taylor B, Jin Q, Nguyen-Tran V, Meeusen S, Zhang YQ, et al (2015b) Inhibition of DYRK1A and GSK3B induces human \u03b2-cell proliferation. Nat Commun. 6:1\u201311. https:\/\/doi.org\/10.1038\/ncomms9372.","DOI":"10.1038\/ncomms9372"},{"key":"255_CR149","doi-asserted-by":"publisher","unstructured":"Shen W, Taylor B, Jin Q, Nguyen-Tran V, Meeusen S, Zhang YQ, et al (2015c) Inhibition of DYRK1A and GSK3B induces human \u03b2-cell proliferation. Nat Commun 6. https:\/\/doi.org\/10.1038\/NCOMMS9372,.","DOI":"10.1038\/NCOMMS9372"},{"key":"255_CR150","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/JDI.14002","volume":"14","author":"J Shirakawa","year":"2023","unstructured":"Shirakawa J (2023) Signaling pathways that regulate adaptive \u03b2-cell proliferation for the treatment of diabetes. J Diabetes Investig.14:735\u201340. https:\/\/doi.org\/10.1111\/JDI.14002.","journal-title":"J Diabetes Investig"},{"key":"255_CR151","doi-asserted-by":"publisher","first-page":"11692","DOI":"10.1073\/PNAS.1102715108\/SUPPL_FILE\/PNAS.201102715SI.PDF","volume":"108","author":"N Soltani","year":"2011","unstructured":"Soltani N, Qiu H, Aleksic M, Glinka Y, Zhao F, Liu R, et al (2011) GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci U S A. 108:11692\u20137. https:\/\/doi.org\/10.1073\/PNAS.1102715108\/SUPPL_FILE\/PNAS.201102715SI.PDF.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"255_CR152","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000119407","volume":"188","author":"B Soria","year":"2008","unstructured":"Soria B, Bedoya FJ, Tejedo JR, Hmadcha A, Ruiz-Salmer\u00f3n R, Lim S, et al (2008) Cell therapy for diabetes mellitus: an opportunity for stem cells? Cells Tissues Organs. 188:70\u20137. https:\/\/doi.org\/10.1159\/000119407.","journal-title":"Cells Tissues Organs"},{"key":"255_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/J.LFS.2024.122645","volume":"346","author":"R Spezani","year":"2024","unstructured":"Spezani R, Reis-Barbosa PH, Mandarim-de-Lacerda CA (2024) Update on the transdifferentiation of pancreatic cells into functional beta cells for treating diabetes. Life Sci.346: 122645. https:\/\/doi.org\/10.1016\/J.LFS.2024.122645.","journal-title":"Life Sci"},{"key":"255_CR154","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.2337\/DB14-1843","volume":"64","author":"AF Stewart","year":"2015","unstructured":"Stewart AF, Hussain MA, Garc\u00eda-Oca\u00f1a A, Vasavada RC, Bhushan A, Bernal-Mizrachi E, et al (2015) Human \u03b2-cell proliferation and intracellular signaling: part 3. Diabetes. 64:1872\u201385. https:\/\/doi.org\/10.2337\/DB14-1843.","journal-title":"Diabetes"},{"key":"255_CR155","doi-asserted-by":"publisher","unstructured":"Sun Z, Jiang Q, Li J, Guo J (2020) The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis. Signal Transduct Target Ther. 5:1\u201315. https:\/\/doi.org\/10.1038\/s41392-020-00265-w.","DOI":"10.1038\/s41392-020-00265-w"},{"key":"255_CR156","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/J.DSX.2018.10.008","volume":"13","author":"SY Tan","year":"2019","unstructured":"Tan SY, Mei Wong JL, Sim YJ, Wong SS, Mohamed Elhassan SA, Tan SH, et al (2019) Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr Clin Res Rev. 13:364\u201372. https:\/\/doi.org\/10.1016\/J.DSX.2018.10.008.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"255_CR157","doi-asserted-by":"publisher","DOI":"10.1002\/CBF.3967","volume":"42","author":"J Tasnim","year":"2024","unstructured":"Tasnim J, Hashim NM, Han HC (2024) A comprehensive review on potential drug\u2013drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors. Cell Biochem Funct. 42: e3967. https:\/\/doi.org\/10.1002\/CBF.3967.","journal-title":"Cell Biochem Funct"},{"key":"255_CR158","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2042018815580257","volume":"6","author":"SH Tella","year":"2015","unstructured":"Tella SH, Rendell MS (2015) Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab.6:109\u201334. https:\/\/doi.org\/10.1177\/2042018815580257.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"255_CR159","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/CBDD.13979","volume":"99","author":"R Thilagavathi","year":"2022","unstructured":"Thilagavathi R, Hosseini-Zare MS, Malini M, Selvam C (2022) A comprehensive review on glucokinase activators: promising agents for the treatment of type 2 diabetes. Chem Biol Drug Des. 99:247\u201363. https:\/\/doi.org\/10.1111\/CBDD.13979.","journal-title":"Chem Biol Drug Des"},{"key":"255_CR160","doi-asserted-by":"publisher","first-page":"5578265","DOI":"10.1155\/2021\/5578265","volume":"2021","author":"A Trang","year":"2021","unstructured":"Trang A, Bushman J, Halalau A (2021) Effect of Long-Term Proton Pump Inhibitor Use on Glycemic Control in Patients with Type Two Diabetes Mellitus. J Diabetes Res. 5578265. https:\/\/doi.org\/10.1155\/2021\/5578265.","journal-title":"J Diabetes Res"},{"key":"255_CR161","doi-asserted-by":"publisher","unstructured":"Trang A, Bushman J, Halalau A (2021a) Effect of Long-Term Proton Pump Inhibitor Use on Glycemic Control in Patients with Type Two Diabetes Mellitus. J Diabetes Res. 2021. https:\/\/doi.org\/10.1155\/2021\/5578265.","DOI":"10.1155\/2021\/5578265"},{"key":"255_CR162","doi-asserted-by":"publisher","unstructured":"Lin H-M, Lee J-H, Yadav H, Kamaraju AK, Liu E, Zhigang D, et al (2009) Transforming Growth Factor-\/Smad3 Signaling Regulates Insulin Gene Transcription and Pancreatic Islet-Cell Function * \u25a1 S. https:\/\/doi.org\/10.1074\/jbc.M805379200.","DOI":"10.1074\/jbc.M805379200"},{"key":"255_CR163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-025-85178-w","volume":"15","author":"S Ullsten","year":"2025","unstructured":"Ullsten S, \u00d8stnes Hansen K, Petit GA, Hansen EH, Andersen JH (2025) Promotion of beta cell proliferation through DYRK kinase inhibition using the marine natural product breitfussin C. Sci Rep. 15:1\u20138. https:\/\/doi.org\/10.1038\/s41598-025-85178-w.","journal-title":"Sci Rep"},{"key":"255_CR164","doi-asserted-by":"publisher","unstructured":"Vetere A, Choudhary A, Burns SM, Wagner BK (2014) Targeting the pancreatic \u03b2-cell to treat diabetes. Nat Rev Drug Discov. 13:278\u201389. https:\/\/doi.org\/10.1038\/nrd4231.","DOI":"10.1038\/nrd4231"},{"key":"255_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/J.CBPA.2022.102150","volume":"68","author":"BK Wagner","year":"2022","unstructured":"Wagner BK (2022) Small-molecule discovery in the pancreatic beta cell. Curr Opin Chem Biol. 68: 102150. https:\/\/doi.org\/10.1016\/J.CBPA.2022.102150.","journal-title":"Curr Opin Chem Biol"},{"key":"255_CR166","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/DDDT.S10180","volume":"4","author":"E Wajcberg","year":"2010","unstructured":"Wajcberg E, Amarah A (2010) Liraglutide in the management of type 2 diabetes. Drug des Devel Ther.4:279. https:\/\/doi.org\/10.2147\/DDDT.S10180.","journal-title":"Drug des Devel Ther"},{"key":"255_CR167","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0260","author":"W Wang","year":"2021","unstructured":"Wang W, Zhang C. Targeting \u03b2-Cell Dedifferentiation and Transdifferentiation: Opportunities and Challenges. 2021. https:\/\/doi.org\/10.1530\/EC-21-0260.","journal-title":"Targeting \u03b2-Cell Dedifferentiation and Transdifferentiation: Opportunities and Challenges"},{"key":"255_CR168","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nm.3820","volume":"21","author":"P Wang","year":"2015","unstructured":"Wang P, Alvarez-Perez JC, Felsenfeld DP, Liu H, Sivendran S, Bender A, et al (2015) A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat Med. 21:383\u20138. https:\/\/doi.org\/10.1038\/nm.3820.","journal-title":"Nat Med"},{"key":"255_CR169","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.cmet.2018.12.005","volume":"29","author":"P Wang","year":"2019","unstructured":"Wang P, Karakose E, Liu H, Swartz E, Ackeifi C, Zlatanic V, et al (2019) Combined Inhibition of DYRK1A, SMAD and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells of the overall strategy HHS Public Access. Cell Metab. 29:638\u201352. https:\/\/doi.org\/10.1016\/j.cmet.2018.12.005.","journal-title":"Cell Metab"},{"issue":"1","key":"255_CR170","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4252\/WJSC.V13.I1.64","volume":"13","author":"KL Wang","year":"2021","unstructured":"Wang KL, Tao M, Wei TJ, Wei R (2021) Pancreatic \u03b2 cell regeneration induced by clinical and preclinical agents. World J Stem Cells. 13(1):64. https:\/\/doi.org\/10.4252\/WJSC.V13.I1.64.","journal-title":"World J Stem Cells"},{"key":"255_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/FCVM.2022.981982","volume":"9","author":"J Wang","year":"2023","unstructured":"Wang J, An M, Haubner BJ, Penninger JM (2023) Cardiac regeneration: Options for repairing the injured heart. Front Cardiovasc Med. 9: 981982. https:\/\/doi.org\/10.3389\/FCVM.2022.981982.","journal-title":"Front Cardiovasc Med"},{"key":"255_CR172","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.17.594179","author":"P Wang","year":"2024","unstructured":"Wang P, Wood O, Choleva L, Liu H, Karakose E, Lambertini L, et al (2024) Select DYRK1A Inhibitors Enhance Both Proliferation and Differentiation in Human Pancreatic Beta Cells. BioRxiv Prepr Serv Biol. https:\/\/doi.org\/10.1101\/2024.05.17.594179.","journal-title":"BioRxiv Prepr Serv Biol"},{"key":"255_CR173","doi-asserted-by":"publisher","unstructured":"Winzell MS, Levine F (2022) Approaches to Inducing \u03b2-Cell Regeneration. Biomed. 10:571. https:\/\/doi.org\/10.3390\/BIOMEDICINES10030571.","DOI":"10.3390\/BIOMEDICINES10030571"},{"key":"255_CR174","doi-asserted-by":"publisher","unstructured":"Xiang B, Chen L, Wang X, Zhao Y, Wang Y, Xiang C (2017) Transplantation of Menstrual Blood-Derived Mesenchymal Stem Cells Promotes the Repair of LPS-Induced Acute Lung Injury. Int J Mol Sci.18:689. https:\/\/doi.org\/10.3390\/IJMS18040689.","DOI":"10.3390\/IJMS18040689"},{"key":"255_CR175","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1007\/S00125-015-3670-0","volume":"58","author":"Y Xu","year":"2015","unstructured":"Xu Y, Wang X, Gao L, Zhu J, Zhang H, Shi H, et al (2015) Prolactin-stimulated survivin induction is required for beta cell mass expansion during pregnancy in mice. Diabetologia. 58:2064\u201373. https:\/\/doi.org\/10.1007\/S00125-015-3670-0.","journal-title":"Diabetologia"},{"key":"255_CR176","doi-asserted-by":"publisher","unstructured":"Xu T, Yang L, Yan C, Wang Xiaoxia, Huang P, Zhao F, et al (2014) The IRE1\u03b1-XBP1 pathway regulates metabolic stress-induced compensatory proliferation of pancreatic \u03b2-cells. Cell Res 24:1137\u201340. https:\/\/doi.org\/10.1038\/cr.2014.55.","DOI":"10.1038\/cr.2014.55"},{"key":"255_CR177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2016.06.009","volume":"49","author":"G Xue","year":"2016","unstructured":"Xue G, Romano E, Massi D, Mandal\u00e0 M (2016) Wnt\/\u03b2-catenin signaling in melanoma: preclinical rationale and novel therapeutic insights. Cancer Treat Rev. 49:1\u201312. https:\/\/doi.org\/10.1016\/j.ctrv.2016.06.009.","journal-title":"Cancer Treat Rev"},{"key":"255_CR178","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1097\/TP.0B013E3181D98AF1","volume":"89","author":"T Yamamoto","year":"2010","unstructured":"Yamamoto T, Mita A, Ricordi C, Messinger S, Miki A, Sakuma Y, et al (2010) Prolactin supplementation to culture medium improves \u03b2-cell survival. Transplantation. 89:1328\u201335. https:\/\/doi.org\/10.1097\/TP.0B013E3181D98AF1.","journal-title":"Transplantation"},{"key":"255_CR179","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/MT.2015.181\/ATTACHMENT\/E69690BD-3D19-4FBB-8B7C-887DFF4682A9\/MMC2.PPT","volume":"24","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Fava GE, Wang H, Mauvais-Jarvis F, Fonseca VA, Wu H (2016) PAX4 gene transfer induces \u03b1-to-\u03b2 cell phenotypic conversion and confers therapeutic benefits for diabetes treatment. Mol Ther. 24:251\u201360. https:\/\/doi.org\/10.1038\/MT.2015.181\/ATTACHMENT\/E69690BD-3D19-4FBB-8B7C-887DFF4682A9\/MMC2.PPT.","journal-title":"Mol Ther"},{"key":"255_CR180","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/S41591-022-01802-6","volume":"28","author":"D Zhu","year":"2022","unstructured":"Zhu D, Li Xiaoying, Ma J, Zeng J, Gan S, Dong X, et al (2022) Dorzagliatin in drug-na\u00efve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 28:965\u201373. https:\/\/doi.org\/10.1038\/S41591-022-01802-6.","journal-title":"Nat Med"},{"key":"255_CR181","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/DOM.13338","volume":"20","author":"XX Zhu","year":"2018","unstructured":"Zhu XX, Zhu DL, Li XY, Li YL, Jin XW, Hu TX, et al (2018) Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic \u03b2-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection. Diabetes, Obes Metab. 20:2113\u201320. https:\/\/doi.org\/10.1111\/DOM.13338.","journal-title":"Diabetes, Obes Metab"}],"container-title":["Cell Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13619-025-00255-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13619-025-00255-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13619-025-00255-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T01:01:51Z","timestamp":1757120511000},"score":1,"resource":{"primary":{"URL":"https:\/\/cellregeneration.springeropen.com\/articles\/10.1186\/s13619-025-00255-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":181,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["255"],"URL":"https:\/\/doi.org\/10.1186\/s13619-025-00255-9","relation":{},"ISSN":["2045-9769"],"issn-type":[{"value":"2045-9769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}